CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 56 enrolled
Drug / intervention
Paliperidone palmitatedrug
Likely dose
Paliperidone palmitate 150 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01606254
NCT01606254Phase 2Completed
CompareCT.gov

A Repeated Dose Study of JNS010 (Paliperidone Palmitate) in Patients With Schizophrenia

Janssen Pharmaceutical K.K.·interventional·Posted May 25, 2012·Updated Jun 5, 2013

In Brief

A Phase 2 clinical trial evaluating Paliperidone palmitate for Schizophrenia. Completed, enrolled 56 participants across 1 site.

Detailed Summary

The purpose of this study is to assess the pharmacokinetics (the study of the way a drug enters and leaves the blood and tissues over time) and safety of paliperidone palmitate in participants with schizophrenia (psychiatric disorder with symptoms of emotional instability, detachment from reality, often with delusions and hallucinations, and withdrawal into the self).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSchizophrenia
CountriesJapan
Collaborators--

Timeline

Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMay 25, 2012
Enrollment StartJan 1, 2007
Primary CompletionApr 1, 2008
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 14.1 years ago

Interventions

Paliperidone palmitatedrug

Paliperidone palmitate aqueous suspension for injection 0.5, 1.0, 1.5 milliliter equivalent to 50, 100, 150 mg paliperidone respectively as intramuscular injection on Days 1, 8, 36 and 64.